 |
0 Diseases |  |
17 Trials |
|
17 Trials |  |
629 News |  |
| «12345678910» |
- Lumigan (bimatoprost) / Senju, AbbVie
Enrollment change, Trial termination, Trial primary completion date: Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA) (clinicaltrials.gov) - Mar 17, 2017
P1, N=53, Terminated, Sponsor: Allergan
N=90 --> 53 | Recruiting --> Terminated | Trial primary completion date: Oct 2017 --> Jan 2017
- || Lumigan (bimatoprost) / Senju, AbbVie
Trial primary completion date: Safety of GANFORT (clinicaltrials.gov) - Jan 31, 2017
P4, N=750, Recruiting, Sponsor: Allergan
N=90 --> 53 | Recruiting --> Terminated | Trial primary completion date: Oct 2017 --> Jan 2017 Trial primary completion date: Sep 2017 --> Sep 2018
- || Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) / Novartis
Trial primary completion date: SIMBRINZA (clinicaltrials.gov) - Jan 23, 2017
P4, N=280, Recruiting, Sponsor: Alcon Research
Trial primary completion date: Sep 2017 --> Sep 2018 Trial primary completion date: Feb 2017 --> Feb 2018
- |||| Lumigan (bimatoprost) / Senju, AbbVie
Trial completion: Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension (clinicaltrials.gov) - Dec 12, 2016
P4, N=807, Completed, Sponsor: Allergan
Trial primary completion date: Feb 2017 --> Feb 2018 Active, not recruiting --> Completed
- Lumigan (bimatoprost) / Senju, AbbVie
Enrollment open, Trial initiation date: Topical Bimatoprost for Chemical Blepharoplasty (clinicaltrials.gov) - Dec 8, 2016
P0, N=15, Recruiting, Sponsor: Tulane University
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Aug 2016 --> Nov 2016
- | Lumigan (bimatoprost) / Senju, AbbVie
Trial completion: Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of Male Patients With Androgenetic Alopecia (clinicaltrials.gov) - Oct 26, 2016
P1, N=11, Completed, Sponsor: Allergan
Not yet recruiting --> Recruiting | Initiation date: Aug 2016 --> Nov 2016 Recruiting --> Completed
- |||| Lumigan (bimatoprost) / Senju, AbbVie
Trial completion: Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension (clinicaltrials.gov) - Oct 25, 2016
P1/2, N=109, Completed, Sponsor: Allergan
Recruiting --> Completed Active, not recruiting --> Completed
- || Lumigan (bimatoprost) / Senju, AbbVie
Trial primary completion date: Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA) (clinicaltrials.gov) - Sep 23, 2016
P1, N=90, Recruiting, Sponsor: Allergan
Active, not recruiting --> Completed Trial primary completion date: Apr 2017 --> Oct 2017
- Lumigan (bimatoprost) / Senju, AbbVie
New P1 trial: Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of Male Patients With Androgenetic Alopecia (clinicaltrials.gov) - Jul 28, 2016
P1, N=10, Recruiting, Sponsor: Allergan
- || Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) / Novartis
Trial primary completion date: SIMBRINZA (clinicaltrials.gov) - Jul 27, 2016
P4, N=280, Recruiting, Sponsor: Alcon Research
Trial primary completion date: Apr 2017 --> Oct 2017 Trial primary completion date: Nov 2016 --> Feb 2017
- || Lumigan (bimatoprost) / Senju, AbbVie
Trial primary completion date: Safety of GANFORT (clinicaltrials.gov) - Jul 19, 2016
P4, N=750, Recruiting, Sponsor: Allergan
Trial primary completion date: Nov 2016 --> Feb 2017 Trial primary completion date: Nov 2016 --> Sep 2017
- Lumigan (bimatoprost) / Senju, AbbVie
New trial: Topical Bimatoprost for Chemical Blepharoplasty (clinicaltrials.gov) - Jul 13, 2016
P0, N=15, Not yet recruiting, Sponsor: Tulane University
- Lumigan (bimatoprost) / Senju, AbbVie
Enrollment closed, Trial primary completion date: Cutaneous Prostaglandin Application: Nail Growth, Nail Brittleness, and Eye Pressure (clinicaltrials.gov) - Jun 15, 2016
P=N/A, N=45, Active, not recruiting, Sponsor: Northwestern University
Trial primary completion date: Nov 2016 --> Sep 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Jun 2016
- Lumigan (bimatoprost) / Senju, AbbVie
New trial: Primary Glaucoma Treatment Trial in Kenya and South Africa - SLT vs. Medication (clinicaltrials.gov) - May 18, 2016
P=N/A, N=400, Recruiting, Sponsor: University College, London
- |||| Lumigan (bimatoprost) / Senju, AbbVie, Zioptan (tafluprost) / Santen, Merck (MSD)
Enrollment open: SPORTII: Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml (clinicaltrials.gov) - May 12, 2016
P4, N=67, Recruiting, Sponsor: Universitaire Ziekenhuizen Leuven
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Jun 2016 Not yet recruiting --> Recruiting
- Lumigan (bimatoprost) / Senju, AbbVie
Trial completion, Trial primary completion date: Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study) (clinicaltrials.gov) - May 6, 2016
P4, N=31, Completed, Sponsor: Cardiff University
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Mar 2016
- Lumigan (bimatoprost) / Senju, AbbVie
Enrollment change, Trial withdrawal: Bimatoprost Ophthalmic Solution in Increasing Eyebrow and Eyelash Growth in Patients Who Have Undergone Chemotherapy for Breast Cancer and in Healthy Participants (clinicaltrials.gov) - Apr 7, 2016
P=N/A, N=0, Withdrawn, Sponsor: Jonsson Comprehensive Cancer Center
Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Mar 2016 N=90 --> 0 | Not yet recruiting --> Withdrawn
- ||| Lumigan (bimatoprost) / Senju, AbbVie
Enrollment open: Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA) (clinicaltrials.gov) - Mar 31, 2016
P1, N=90, Recruiting, Sponsor: Allergan
N=90 --> 0 | Not yet recruiting --> Withdrawn Not yet recruiting --> Recruiting
- || Lumigan (bimatoprost) / Senju, AbbVie
Trial primary completion date: Safety and Efficacy Assessment of Monoprost (clinicaltrials.gov) - Mar 18, 2016
P4, N=396, Recruiting, Sponsor: Laboratoires Thea
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2015 --> Jul 2016
- ||| Lumigan (bimatoprost) / Senju, AbbVie
New P1 trial: Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA) (clinicaltrials.gov) - Feb 8, 2016
P1, N=90, Not yet recruiting, Sponsor: Allergan
- |||| Lumigan (bimatoprost) / Senju, AbbVie
Enrollment open: Safety of GANFORT (clinicaltrials.gov) - Nov 21, 2015
P4, N=750, Recruiting, Sponsor: Allergan
Trial primary completion date: Dec 2015 --> Jul 2016 Not yet recruiting --> Recruiting
- ||||| Lumigan (bimatoprost) / Senju, AbbVie
New P4 trial: Safety of GANFORT (clinicaltrials.gov) - Oct 22, 2015
P4, N=750, Not yet recruiting, Sponsor: Allergan
- Lumigan (bimatoprost) / Senju, AbbVie
Trial initiation date, Trial primary completion date: Bimatoprost Ophthalmic Solution in Increasing Eyebrow and Eyelash Growth in Patients Who Have Undergone Chemotherapy for Breast Cancer and in Healthy Participants (clinicaltrials.gov) - Sep 8, 2015
P=N/A, N=90, Not yet recruiting, Sponsor: Jonsson Comprehensive Cancer Center
Not yet recruiting --> Recruiting Initiation date: Jan 2015 --> Jan 2016 | Trial primary completion date: Aug 2015 --> Aug 2017
- |||| Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) / Novartis
Enrollment open: SIMBRINZA (clinicaltrials.gov) - Aug 13, 2015
P4, N=280, Recruiting, Sponsor: Alcon Research
Initiation date: Jan 2015 --> Jan 2016 | Trial primary completion date: Aug 2015 --> Aug 2017 Not yet recruiting --> Recruiting
- ||| Lumigan (bimatoprost) / Senju, AbbVie
New trial: Safety and Patient Satisfaction With GLASH VISTA (clinicaltrials.gov) - Jul 22, 2015
P=N/A, N=1500, Recruiting, Sponsor: Allergan
- |||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Trial completion: Patient Satisfaction Study of Combined Facial Treatment With BOTOX (clinicaltrials.gov) - Jul 17, 2015
P4, N=100, Completed, Sponsor: Allergan
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Lumigan (bimatoprost) / Senju, AbbVie
Trial initiation date: An Efficacy and Tolerability Study of TRAVATAN (clinicaltrials.gov) - Jul 14, 2015
P4, N=104, Completed, Sponsor: Alcon Research
Active, not recruiting --> Completed Initiation date: Dec 2012 --> Sep 2012
- Lumigan (bimatoprost) / Senju, AbbVie
Enrollment open, Trial initiation date: Treatment of Soft Tissue Expansion in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues (clinicaltrials.gov) - Jun 16, 2015
P3, N=20, Recruiting, Sponsor: Rabin Medical Center
Initiation date: Dec 2012 --> Sep 2012 Not yet recruiting --> Recruiting | Initiation date: Jun 2014 --> Nov 2014
- ||||| Lumigan (bimatoprost) / Senju, AbbVie, Zioptan (tafluprost) / Santen, Merck (MSD)
New P4 trial: SPORTII: Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml (clinicaltrials.gov) - Jun 15, 2015
P4, N=67, Not yet recruiting, Sponsor: Universitaire Ziekenhuizen Leuven
- Lumigan (bimatoprost) / Senju, AbbVie
New trial: Cutaneous Prostaglandin Application: Nail Growth, Nail Brittleness, and Eye Pressure (clinicaltrials.gov) - May 19, 2015
P=N/A, N=45, Recruiting, Sponsor: Northwestern University
- || Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Trial primary completion date: Patient Satisfaction Study of Combined Facial Treatment With BOTOX (clinicaltrials.gov) - Apr 25, 2015
P4, N=100, Active, not recruiting, Sponsor: Allergan
Not yet recruiting --> Recruiting | Initiation date: Jun 2014 --> Nov 2014 Trial primary completion date: Feb 2015 --> Jun 2015
- ||||| Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) / Novartis
New P4 trial: SIMBRINZA (clinicaltrials.gov) - Apr 17, 2015
P4, N=280, Not yet recruiting, Sponsor: Alcon Research
- Lumigan (bimatoprost) / Senju, AbbVie
Enrollment closed: Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study) (clinicaltrials.gov) - Apr 16, 2015
P4, N=31, Active, not recruiting, Sponsor: Cardiff University
Trial primary completion date: Feb 2015 --> Jun 2015 Recruiting --> Active, not recruiting
- |||| Lumigan (bimatoprost) / Senju, AbbVie
Trial completion, Trial primary completion date: An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension (clinicaltrials.gov) - Apr 16, 2015
P4, N=93, Completed, Sponsor: Allergan
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Mar 2015 --> Oct 2014
- |||| Lumigan (bimatoprost) / Senju, AbbVie
Trial completion: A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA) (clinicaltrials.gov) - Apr 13, 2015
P2, N=246, Completed, Sponsor: Allergan
Active, not recruiting --> Completed | Trial primary completion date: Mar 2015 --> Oct 2014 Active, not recruiting --> Completed
- Lumigan (bimatoprost) / Senju, AbbVie
Trial completion: Intraocular Pressure and Tolerability Study of Preservative-free Prostaglandins (Bimatoprost and Latanoprost) on Glaucoma and Ocular Hypertension: European, Multicentric, Investigator-led, Single Masked Study (clinicaltrials.gov) - Mar 18, 2015
P4, N=67, Completed, Sponsor: Association for Innovation and Biomedical Research on Light and Image
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Enrollment closed: Patient Satisfaction Study of Combined Facial Treatment With BOTOX (clinicaltrials.gov) - Feb 13, 2015
P4, N=100, Active, not recruiting, Sponsor: Allergan
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Lumigan (bimatoprost) / Senju, AbbVie
Enrollment closed, Trial primary completion date: Intraocular Pressure and Tolerability Study of Preservative-free Prostaglandins (Bimatoprost and Latanoprost) on Glaucoma and Ocular Hypertension: European, Multicentric, Investigator-led, Single Masked Study (clinicaltrials.gov) - Jan 30, 2015
P4, N=67, Active, not recruiting, Sponsor: Association for Innovation and Biomedical Research on Light and Image
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2014 --> Feb 2015
- ||| Lumigan (bimatoprost) / Senju, AbbVie
Enrollment closed: Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension (clinicaltrials.gov) - Jan 26, 2015
P4, N=807, Active, not recruiting, Sponsor: Allergan
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2014 --> Feb 2015 Recruiting --> Active, not recruiting
- | Lumigan (bimatoprost) / Senju, AbbVie
Trial completion, Trial primary completion date: Safety and Efficacy of Bimatoprost 0.03% Solution for the Treatment of Thinning Eyebrows (clinicaltrials.gov) - Jan 15, 2015
P4, N=33, Completed, Sponsor: ATS Clinical Research
Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Jun 2014 --> Sep 2014
- Lumigan (bimatoprost) / Senju, AbbVie
Enrollment change, Trial termination, Trial primary completion date: A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paediatric Patients With Glaucoma (clinicaltrials.gov) - Dec 24, 2014
P3, N=6, Terminated, Sponsor: Allergan
Recruiting --> Completed | Trial primary completion date: Jun 2014 --> Sep 2014 N=120 --> 6 | Recruiting --> Terminated | Trial primary completion date: Mar 2015 --> Oct 2014; Study terminated due to corporate decision.
- Lumigan (bimatoprost) / Senju, AbbVie
Enrollment open, Trial initiation date, Trial primary completion date: Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study) (clinicaltrials.gov) - Dec 17, 2014
P4, N=31, Recruiting, Sponsor: Cardiff University
N=120 --> 6 | Recruiting --> Terminated | Trial primary completion date: Mar 2015 --> Oct 2014; Study terminated due to corporate decision. Not yet recruiting --> Recruiting | Initiation date: May 2014 --> Nov 2014 | Trial primary completion date: Feb 2015 --> Dec 2015
- ||| Lumigan (bimatoprost) / Senju, AbbVie
Enrollment closed: Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension (clinicaltrials.gov) - Dec 12, 2014
P4, N=100, Active, not recruiting, Sponsor: Allergan
Not yet recruiting --> Recruiting | Initiation date: May 2014 --> Nov 2014 | Trial primary completion date: Feb 2015 --> Dec 2015 Recruiting --> Active, not recruiting
- || Lumigan (bimatoprost) / Senju, AbbVie
Trial primary completion date: Safety and Efficacy Assessment of Monoprost (clinicaltrials.gov) - Oct 17, 2014
P4, N=396, Recruiting, Sponsor: Laboratoires Thea
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2014 --> Dec 2015
- ||| Lumigan (bimatoprost) / Senju, AbbVie
Enrollment closed, Enrollment change, Trial primary completion date: Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension (clinicaltrials.gov) - Oct 2, 2014
P1/2, N=109, Active, not recruiting, Sponsor: Allergan
Trial primary completion date: Sep 2014 --> Dec 2015 Recruiting --> Active, not recruiting | N=200 --> 109 | Trial primary completion date: Jan 2017 --> Sep 2016
- ||| Lumigan (bimatoprost) / Senju, AbbVie
Trial completion: Tolerability of Bimatoprost 0.01% vs Latanoprost Eye Drops (clinicaltrials.gov) - Sep 28, 2014
P=N/A, N=211, Completed, Sponsor: MDbackline, LLC
Recruiting --> Active, not recruiting | N=200 --> 109 | Trial primary completion date: Jan 2017 --> Sep 2016 Recruiting --> Completed
- |||| Lumigan (bimatoprost) / Senju, AbbVie
Trial completion, Enrollment change: APPEAL-Taiwan: A Study of Bimatoprost 0.01% in the Clinical Setting (clinicaltrials.gov) - Sep 22, 2014
P4, N=310, Completed, Sponsor: Allergan
Recruiting --> Completed Active, not recruiting --> Completed | N=400 --> 310
- ||| Lumigan (bimatoprost) / Senju, AbbVie
Enrollment closed: An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension (clinicaltrials.gov) - Aug 28, 2014
P4, N=93, Active, not recruiting, Sponsor: Allergan
Active, not recruiting --> Completed | N=400 --> 310 Recruiting --> Active, not recruiting
- |||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Enrollment open: Patient Satisfaction Study of Combined Facial Treatment With BOTOX (clinicaltrials.gov) - Aug 15, 2014
P4, N=100, Recruiting, Sponsor: Allergan
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- || Lumigan (bimatoprost) / Senju, AbbVie
Trial primary completion date: Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension (clinicaltrials.gov) - Jul 12, 2014
P1/2, N=200, Recruiting, Sponsor: Allergan
Not yet recruiting --> Recruiting Trial primary completion date: Mar 2016 --> Jan 2017